<DOC>
	<DOCNO>NCT02049034</DOCNO>
	<brief_summary>Glucagon-like-peptide-1 ( GLP-1 ) analogues new treatment type 2 diabetes , recently show beneficial effect weight , glycaemic control postprandial triglyceride concentration . Postprandial hypertriglyceridaemia , associate increase risk cardiovascular disease , feature type 2 diabetes . Hypertriglyceridaemia due excess triglyceride-rich lipoprotein ( TRL ) consist low-density lipoprotein , ( VLDL ) synthesise liver contain high molecular weight form apolipoproteinB ( apoB ) , apoB-100 , chylomicron synthesise intestine response intake dietary fat contain low molecular weight form apoB , apoB-48 . A recent study show GLP-1 receptor signal require control postprandial lipoprotein synthesis secretion hamster mice . GLP-1 show reduce apoB-48 TRL production GLP-1 receptor antagonist increase apoB-48 TRL production . This study investigate effect GLP-1 analogue lixisenatide compare placebo , double blind crossover study , postprandial triglyceride metabolism 12 patient type 2 diabetes . Chylomicron VLDL production clearance rate measure repeated meal study label apoB-100 apoB-48 labelling triglyceride use stable isotope methodology . Glucose flux response mixed fluid meal also investigate use stable isotope methodology . Gastric empty post heparin LPL activity measure . The hypothesis ] lixisenatide lower postprandial glycaemia due decrease endogenous glucose output increase glucose clearance peripheral tissue result improvement insulin sensitivity .</brief_summary>
	<brief_title>Lixisenatide-The Effects Glucose Lipid Metabolism Type 2 Diabetes</brief_title>
	<detailed_description>GLP-1 analogues new treatment type 2 diabetes , recently show beneficial effect weight , glycaemic control postprandial triglyceride concentration . Postprandial hypertriglyceridaemia , associate increase risk cardiovascular disease , feature type 2 diabetes . Hypertriglyceridaemia due excess triglyceride-rich lipoprotein ( TRL ) consist low-density lipoprotein , ( VLDL ) synthesise liver contain high molecular weight form apolipoproteinB ( apoB ) , apoB-100 , chylomicron synthesise intestine response intake dietary fat contain low molecular weight form apoB , apoB-48 . A recent study show GLP-1 receptor signal require control postprandial lipoprotein synthesis secretion hamster mice . GLP-1 show reduce apoB-48 TRL production GLP-1 receptor antagonist increase apoB-48 TRL production . This study investigate effect GLP-1 analogue lixisenatide compare placebo , double blind crossover study , postprandial triglyceride metabolism 12 patient type 2 diabetes . Chylomicron VLDL production clearance rate measure repeated meal study ( Visits 4 8 ) label apoB-100 apoB-48 1-13C leucine ( infusion 8 hour ) label triglyceride [ 1,1,2,3,3-2H5 ] glycerol ( bolus injection ) 13C triolein . Blood sample take 4 hour prior 8 hr isotopic infusion measure enrichment apoB-100 apoB-48 1-13C leucine gas chromatography mass spectrometry . At Visits 3 7 , glucose flux response mixed fluid meal contain U-13C glucose investigate . Endogenous glucose production also measure infuse [ 6,6-2H2 ] glucose 6hours . Gastric empty measure acetaminophen ( 1000 mg ) absorption . Patients also receive heparin ( 50U/kg ) end study 15 minute blood sample take determine post heparin lipoprotein lipase ( LPL ) activity . During study patient ask monitor blood glucose three day continuous glucose monitoring fill 7 day food diary . The hypothesis ] lixisenatide lower postprandial glycaemia due decrease endogenous glucose output increase glucose clearance peripheral tissue result improvement insulin sensitivity . ii ] lixisenatide reduce postprandial triglyceride due decrease chylomicron production result direct effect enterocyte chylomicron assembly also reduce VLDL secretion liver result improvement insulin sensitivity .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Subjects type 2 diabetes inadequately control metformin . Stable diabetes management last 3 month : metformin dose unchanged . HbA1c know change &gt; 0.5 % 3 month . Caucasian Male 4065 year ( inclusive ) HbA1c 7.59.5 % ( inclusive ) BMI 2740 kg/m2 ( inclusive ) Able willing selfadminister placebo/lixisenatide injection Able willing perform selfblood glucose monitoring . Able willing wear Continuous Glucose Monitoring System ( CGMS ) 3 day Subjects treated insulin , oral hypoglycaemic agent ( OHA ) ( metformin ) , insulin secretagogue Thiazolidinediones ( TZDs ) A history heavy alcohol use ( &gt; 12 15 g alcohol per day ) Arteriopathy History significant coronary artery disease ( myocardial infarction , surgical percutaneous [ balloon and/or stent ] coronary revascularization procedure , coronary angiography show least one stenosis ≥ 50 % major epicardial artery branch vessel ) Ischemic cerebrovascular disease , include : History ischemic stroke . History carotid arterial disease document ≥ 50 % stenosis document carotid ultrasound , magnetic resonance imaging angiography , without neurological sequela . Atherosclerotic peripheral arterial disease , document history amputation due vascular disease ; history surgical percutaneous revascularization procedure ; current symptom intermittent claudication confirm anklebrachial pressure index le 0.9 Hepatic disease : alanine transaminase ( ALT ) &gt; 3 time upper limit normal ( ULN ) Renal disease : estimate glomerular filtration rate ( CockroftGault equation ) less 40ml/minute . Subjects receive fibrates weight reduce drug Mental incapacity Unwillingness language barrier preclude adequate understanding cooperation Fasting plasma triglyceride &gt; 4.0 mmol/l Systolic blood pressure &gt; 160 mmHg 2 occasion , measure least 10minutes apart Screening amylase and/or lipase &gt; 3 time ULN Pcalcitonin ≥20 pg/ml ( 5.9 pmol/L ) . Personal immediate family history medullary thyroid cancer ( MTC ) genetic condition predisposes MTC ( e.g . multiple endocrine neoplasia syndrome ) . History unexplained pancreatitis , chronic pancreatitis , pancreatectomy . Any stomach/gastric surgery minor endoscopic procedure peptic ulcer injection Allergic reaction GLP1 receptor agonist metacresol . Clinically relevant history gastrointestinal disease associate prolonged nausea vomit . Current smoker Subject enrol another experimental protocol involve use investigational drug device</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>GLP-1 agonist</keyword>
	<keyword>Lixisenatide</keyword>
	<keyword>Postprandial glucose metabolism</keyword>
	<keyword>Postprandial lipid metabolism</keyword>
	<keyword>Gastric empty</keyword>
	<keyword>Lipoprotein lipase activity</keyword>
</DOC>